

# Miguel A Perales

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5224663/publications.pdf>

Version: 2024-02-01

289  
papers

15,022  
citations

22132

59  
h-index

25770

108  
g-index

295  
all docs

295  
docs citations

295  
times ranked

13371  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Effect of Neutropenia and Filgrastim (G-CSF) on Cancer Patients With Coronavirus Disease 2019 (COVID-19) Infection. <i>Clinical Infectious Diseases</i> , 2022, 74, 567-574.	2.9	26
2	Human Herpesvirus 6 DNAemia Is Associated With Worse Survival After Ex Vivo T-Cell-Depleted Hematopoietic Cell Transplant. <i>Journal of Infectious Diseases</i> , 2022, 225, 453-464.	1.9	2
3	The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT. <i>Blood Advances</i> , 2022, 6, 1525-1535.	2.5	17
4	Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 48.e1-48.e10.	0.6	18
5	Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 55.e1-55.e5.	0.6	5
6	Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2022, 6, 1054-1063.	2.5	12
7	Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2022, 40, 356-368.	0.8	79
8	Impact of Letermovir Primary Cytomegalovirus Prophylaxis on 1-Year Mortality After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 795-804.	2.9	20
9	Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab. <i>Blood Advances</i> , 2022, 6, 1432-1443.	2.5	13
10	Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant. <i>Blood</i> , 2022, 139, 2758-2769.	0.6	25
11	Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 369-381.	0.8	60
12	Impact of omitting post-transplant minidose-methotrexate doses in allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, 63, 1686-1693.	0.6	2
13	Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 640-654.	13.9	586
14	Ionizing radiation exposure after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 827-829.	1.3	2
15	Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. <i>Nature Medicine</i> , 2022, 28, 713-723.	15.2	117
16	Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML. <i>Blood</i> , 2022, 139, 3546-3557.	0.6	37
17	CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis. <i>Bone Marrow Transplantation</i> , 2022, 57, 1101-1107.	1.3	3
18	Outcomes of Refractory Cytomegalovirus Infection in the First Year after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 403.e1-403.e7.	0.6	4

#	ARTICLE	IF	CITATIONS
19	Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogeneic stem cell transplant. Bone Marrow Transplantation, 2022, 57, 1095-1100.	1.3	4
20	Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 485.e1-485.e6.	0.6	0
21	Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. Cancer Cell, 2022, 40, 590-591.	7.7	70
22	A compilation of fecal microbiome shotgun metagenomics from hematopoietic cell transplantation patients. Scientific Data, 2022, 9, 219.	2.4	11
23	MAIT and V $\alpha$ 2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT. Science Translational Medicine, 2022, 14, .	5.8	19
24	Real-World Evidence of Axicabtagene Ciloleucl for the Treatment of Large B Cell Lymphoma in the United States. Transplantation and Cellular Therapy, 2022, 28, 581.e1-581.e8.	0.6	61
25	ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy. Transplantation and Cellular Therapy, 2022, 28, 523-529.	0.6	7
26	Chimeric antigen receptor T cells and management of toxicities: implications of biomarkers. , 2022, , 245-281.		0
27	Racial disparities in access to alternative donor allografts persist in the era of "donors for all". Blood Advances, 2022, 6, 5625-5629.	2.5	12
28	Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2022, 28, 546-559.	0.6	16
29	Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults. Blood Advances, 2022, 6, 6291-6300.	2.5	11
30	Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. Transplantation and Cellular Therapy, 2022, 28, 681-693.	0.6	13
31	Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. Bone Marrow Transplantation, 2022, 57, 1477-1488.	1.3	28
32	Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucl and Tisagenlecleucl for Relapsed/Refractory Aggressive B Cell Lymphomas. Transplantation and Cellular Therapy, 2022, 28, 669-676.	0.6	36
33	Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulin. Leukemia, 2021, 35, 850-862.	3.3	8
34	The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation. Blood Reviews, 2021, 46, 100744.	2.8	16
35	Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 289-292.	1.3	4
36	Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. Transplantation and Cellular Therapy, 2021, 27, 85.e1-85.e6.	0.6	25

#	ARTICLE	IF	CITATIONS
37	Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study. <i>Blood</i> , 2021, 137, 1527-1537.	0.6	42
38	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e19-e25.	0.7	6
39	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 6-20.	0.6	45
40	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	3.3	45
41	Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. <i>Lancet Haematology</i> , 2021, 8, e185-e193.	2.2	271
42	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 267.e1-267.e5.	0.6	6
43	The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 233-240.	0.6	24
44	Compilation of longitudinal microbiota data and hospitalome from hematopoietic cell transplantation patients. <i>Scientific Data</i> , 2021, 8, 71.	2.4	19
45	Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. <i>Blood</i> , 2021, 137, 3291-3305.	0.6	85
46	Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 2177-2183.	0.6	2
47	The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T cell therapy. <i>British Journal of Haematology</i> , 2021, 193, 1060-1075.	1.2	13
48	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). <i>Blood Advances</i> , 2021, 5, 2481-2489.	2.5	25
49	Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. <i>Medical Mycology</i> , 2021, 59, 970-979.	0.3	20
50	Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 438.e1-438.e6.	0.6	11
51	Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 920.e1-920.e9.	0.6	1
52	National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2021, 39, 1971-1982.	0.8	90
53	Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation. <i>British Journal of Haematology</i> , 2021, 194, 145-157.	1.2	12
54	Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers. <i>Blood Advances</i> , 2021, 5, 2519-2522.	2.5	10

#	ARTICLE	IF	CITATIONS
55	Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma. <i>Blood Advances</i> , 2021, 5, 2608-2618.	2.5	22
56	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.		298
57	Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation. <i>Blood Advances</i> , 2021, 5, 2879-2889.	2.5	16
58	The post-transplant scoring system (PTSS) is associated with outcomes in patients with MDS after CD34+selected allogeneic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2021, 56, 2749-2754.	1.3	0
59	COVID-19 and Hematopoietic Cell Transplantation Center-Specific Survival Analysis: Can We Adjust for the Impact of the Pandemic? Recommendations of the COVID-19 Task Force of the 2020 Center for International Blood and Marrow Transplantation Research Center Outcomes Forum. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 533-539.	0.6	1
60	Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. <i>Blood Advances</i> , 2021, 5, 3397-3406.	2.5	59
61	Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies. <i>Future Oncology</i> , 2021, 17, 3549-3560.	1.1	10
62	Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2021, 62, 3394-3401.	0.6	17
63	Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy. <i>Blood Cancer Discovery</i> , 2021, 2, 577-585.	2.6	44
64	Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 771.e1-771.e10.	0.6	17
65	Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Allograft Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 852.e1-852.e9.	0.6	0
66	A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 837.e1-837.e10.	0.6	0
67	Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1800-1813.	1.2	55
68	MAIT and V $\alpha$ 2 Unconventional T Cells Predict Favorable Outcome after Allogeneic HCT and Are Supported By a Diverse Intestinal Microbiome. <i>Blood</i> , 2021, 138, 331-331.	0.6	2
69	The Incidence and Impact of Clostridioides Difficile Infection (CDI) on Outcomes after Allogeneic Hematopoietic Cell Transplant (alloHCT) - a CIBMTR Study. <i>Blood</i> , 2021, 138, 2894-2894.	0.6	0
70	Timing and Immune Status after Cellular Therapies Predict Response to COVID-19 Vaccines. <i>Blood</i> , 2021, 138, 3891-3891.	0.6	1
71	Post-Transplant Cyclophosphamide Is Associated with Improved Clinical Outcomes in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 1814-1814.	0.6	0
72	Haematopoietic cell transplantation outcomes are linked to intestinal mycobiota dynamics and an expansion of Candida parapsilosis complex species. <i>Nature Microbiology</i> , 2021, 6, 1505-1515.	5.9	35

#	ARTICLE	IF	CITATIONS
73	Racial Disparities in Access to Alternative Donor Allografts Persist in the Era of "Donors for All". <i>Blood</i> , 2021, 138, 423-423.	0.6	1
74	Interim Results of a Pilot, Prospective, Randomized, Double-Blinded, Vehicle- and Comparator-Controlled Trial on Safety and Efficacy of a Topical Inhibitor of Janus Kinase 1/2 (Ruxolitinib INCB018424 Phosphate 1.5% Cream) for Non-Sclerotic and Superficially Sclerotic Chronic Cutaneous Graft-Versus-Host Disease. <i>Blood</i> , 2021, 138, 3915-3915.	0.6	4
75	Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. <i>Blood</i> , 2021, 138, 429-429.	0.6	9
76	A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma. <i>Blood</i> , 2021, 138, 96-96.	0.6	24
77	Alternative donor transplantation for acute myeloid leukemia in patients aged $\geq 50$ years: young HLA-matched unrelated or haploidentical donor?. <i>Haematologica</i> , 2020, 105, 407-413.	1.7	23
78	Cytomegalovirus Viremia and Death After Hematopoietic Cell Transplantation: More Complex Than $\hat{=}$ To Have and Have Not $\hat{=}$ ?. <i>Clinical Infectious Diseases</i> , 2020, 70, 1534-1535.	2.9	1
79	Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 58-65.	2.0	8
80	Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34+ selected graft. <i>Bone Marrow Transplantation</i> , 2020, 55, 1632-1634.	1.3	0
81	Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 323-332.	2.0	19
82	Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies. <i>Bone Marrow Transplantation</i> , 2020, 55, 157-164.	1.3	39
83	Modern management of relapsed and refractory aggressive B-cell lymphoma: A perspective on the current treatment landscape and patient selection for CAR T-cell therapy. <i>Blood Reviews</i> , 2020, 40, 100640.	2.8	32
84	Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury $\hat{=}$ "Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. <i>JAMA Network Open</i> , 2020, 3, e1918668.	2.8	40
85	Checkpoint inhibitors in AML: are we there yet?. <i>British Journal of Haematology</i> , 2020, 188, 159-167.	1.2	31
86	Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. <i>Blood Advances</i> , 2020, 4, 4669-4678.	2.5	64
87	The gut microbiota is associated with immune cell dynamics in humans. <i>Nature</i> , 2020, 588, 303-307.	13.7	273
88	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	2.5	18
89	Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. <i>Blood Cancer Journal</i> , 2020, 10, 79.	2.8	137
90	Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e235-e236.	2.0	0

#	ARTICLE	IF	CITATIONS
91	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2181-2189.	2.0	51
92	Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. <i>Blood Advances</i> , 2020, 4, 3776-3787.	2.5	162
93	Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2040-2046.	2.0	1
94	How I treat adverse effects of CAR-T cell therapy. <i>ESMO Open</i> , 2020, 4, e000746.	2.0	19
95	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 3977-3989.	2.5	55
96	High progression-free survival after intermediate intensity double unit cord blood transplantation in adults. <i>Blood Advances</i> , 2020, 4, 6064-6076.	2.5	29
97	Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 5414-5424.	2.5	263
98	Use of anti-thymocyte globulin (ATG) for the treatment of pure red cell aplasia and immune-mediated cytopenias after allogeneic hematopoietic cell transplantation: a case series. <i>Bone Marrow Transplantation</i> , 2020, 55, 2326-2330.	1.3	2
99	Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm. <i>Medical Mycology</i> , 2020, 58, 1029-1036.	0.3	17
100	Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy. <i>British Journal of Haematology</i> , 2020, 190, 45-51.	1.2	51
101	DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. <i>Blood Advances</i> , 2020, 4, 3024-3033.	2.5	75
102	Impact of Preemptive Therapy for Cytomegalovirus on Hospitalizations and Cost after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1937-1947.	2.0	11
103	Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2020, 382, 822-834.	13.9	435
104	A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1195-1202.	2.0	40
105	Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1071-1076.	2.0	63
106	Lack of a significant pharmacokinetic interaction between letermovir and calcineurin inhibitors in allogeneic HCT recipients. <i>Bone Marrow Transplantation</i> , 2020, 55, 1687-1689.	1.3	9
107	CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. <i>Bone Marrow Transplantation</i> , 2020, 55, 1525-1532.	1.3	17
108	Characteristics and Impact of Post-Transplant Interdisciplinary Palliative Care Consultation in Older Allogeneic Hematopoietic Cell Transplant Recipients. <i>Journal of Palliative Medicine</i> , 2020, 23, 1653-1657.	0.6	1

#	ARTICLE	IF	CITATIONS
109	Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1239-1246.	2.0	56
110	Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin. <i>Blood Advances</i> , 2020, 4, 191-202.	2.5	36
111	Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. <i>Blood Advances</i> , 2020, 4, 676-686.	2.5	101
112	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35
113	Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. <i>Journal of Clinical Investigation</i> , 2020, 130, 733-747.	3.9	161
114	Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. <i>Journal of Clinical Investigation</i> , 2020, 130, 6656-6667.	3.9	101
115	The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD. <i>Blood</i> , 2020, 136, 130-136.	0.6	97
116	Eligibility Criteria for Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 635-643.	2.3	11
117	Monocyte Reconstitution and Gut Microbiota Composition after Hematopoietic Stem Cell Transplantation. <i>Clinical Hematology International</i> , 2020, 2, 156.	0.7	4
118	Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem Cell Transplant By Venetoclax Combination Therapy. <i>Blood</i> , 2020, 136, 16-17.	0.6	0
119	Clinical Impact of Bridging Therapy Prior to Commercial Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Lymphomas. <i>Blood</i> , 2020, 136, 1-2.	0.6	1
120	Secondary Graft-Versus-Host Disease (GVHD) Prophylaxis with Oral Proteasome Inhibitor Ixazomib Is Associated with Low Incidence of Recurrent, Late Acute and Chronic GVHD and Facilitated Calcineurin Inhibitor Taper within the First Year Post Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 41-42.	0.6	0
121	Preliminary Results of the First-in-Human Study of Nexi-001, a Multi-Antigen Specific CD8+ T Cell Product, in Acute Myeloid Leukemia (AML) Patients with Relapsed Disease after Allogeneic Hematopoietic Cell Transplantation (Allo-HSCT) Demonstrate Early Signs of Safety, Tolerability and Robust Immune Responses. <i>Blood</i> , 2020, 136, 31-33.	0.6	0
122	TCR Repertoires in Graft-Versus-Host-Disease (GVHD)-Target Tissues Reveals Tissue Specificity of the Alloimmune Response. <i>Blood</i> , 2020, 136, 21-23.	0.6	1
123	Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults. <i>Blood</i> , 2020, 136, 30-31.	0.6	0
124	End-of-life care for older AML patients relapsing after allogeneic stem cell transplant at a dedicated cancer center. <i>Bone Marrow Transplantation</i> , 2019, 54, 700-706.	1.3	8
125	Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. <i>Blood</i> , 2019, 134, 924-934.	0.6	199
126	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	3.2	10



#	ARTICLE	IF	CITATIONS
127	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. <i>Leukemia</i> , 2019, 33, 2767-2778.	3.3	47
128	Letemovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience. <i>Transplant Infectious Disease</i> , 2019, 21, e13187.	0.7	62
129	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2113-2123.	2.0	77
130	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2305-2321.	2.0	132
131	Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2398-2407.	2.0	21
132	Urgent Time to Allogeneic Hematopoietic Cell Transplantation: A National Survey of Transplant Physicians and Unrelated Donor Search Coordinators Facilitated by the Histocompatibility Advisory Group to the National Marrow Donor Program. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2501-2506.	2.0	10
133	Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1859-1868.	2.0	58
134	Regarding "Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study" <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e268-e269.	2.0	7
135	Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma. <i>Leukemia</i> , 2019, 33, 2540-2544.	3.3	26
136	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 1868-1880.	1.3	86
137	Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1526-1535.	2.0	15
138	CAR T cells: The future is already present. <i>Medicina Clínica (English Edition)</i> , 2019, 152, 281-286.	0.1	0
139	Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation. <i>JAMA Oncology</i> , 2019, 5, 715.	3.4	44
140	Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. <i>Blood Advances</i> , 2019, 3, 2525-2536.	2.5	13
141	Establishing a standardized system for review and adjudication of chronic graft-versus-host disease data in accordance with the National Institutes Consensus criteria. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e62.	0.6	6
142	Lactose drives <i>Enterococcus</i> expansion to promote graft-versus-host disease. <i>Science</i> , 2019, 366, 1143-1149.	6.0	217
143	CAR T Cell Toxicity: Current Management and Future Directions. <i>HemaSphere</i> , 2019, 3, e186.	1.2	121
144	ASBMT Statement on Routine Prophylaxis for Central Nervous System Recurrence of Acute Lymphoblastic Leukemia following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e86-e88.	2.0	8

#	ARTICLE	IF	CITATIONS
145	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e76-e85.	2.0	85
146	Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 480-487.	2.0	10
147	Cytomegalovirus Infection in Allogeneic Hematopoietic Cell Transplantation Managed by the Preemptive Approach: Estimating the Impact on Healthcare Resource Utilization and Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 791-799.	2.0	7
148	Immune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1136-1141.	2.0	7
149	C�lulas CAR T: el futuro ya es presente. <i>Medicina Cl�nica</i> , 2019, 152, 281-286.	0.3	1
150	Expanding Therapeutic Opportunities for Hematopoietic Stem Cell Transplantation: T Cell Depletion as a Model for the Targeted Allograft. <i>Annual Review of Medicine</i> , 2019, 70, 381-393.	5.0	13
151	Advances in ex vivo T cell depletion - where do we stand?. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e29.	0.6	3
152	A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas. <i>Blood</i> , 2019, 134, 1599-1599.	0.6	45
153	Antibiotic Exposures and Dietary Intakes Are Associated with Changes in Microbiota Compositions in Allogeneic Hematopoietic Stem Cell Transplant Patients. <i>Blood</i> , 2019, 134, 597-597.	0.6	5
154	Making Progress in Graft-Versus-Host Disease Prophylaxis and Microbiome Analysis in the Blood and Marrow Transplant Clinical Trials Network: Progress III (1703)/MI-Immune (1801). <i>Blood</i> , 2019, 134, 2005-2005.	0.6	0
155	The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1322-1340.	2.0	85
156	Severe pembrolizumab-associated neutropenia after CD34+ selected allogeneic hematopoietic-cell transplantation for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2018, 53, 1065-1068.	1.3	9
157	Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2018, 20, e12897.	0.7	11
158	Reprint of: Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S15-S19.	2.0	12
159	Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 871-876.	2.0	35
160	Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1079-1087.	2.0	20
161	Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1274-1280.	2.0	46
162	CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 964-972.	2.0	19

#	ARTICLE	IF	CITATIONS
163	Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 27-31.	2.0	49
164	Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 142-149.	2.0	16
165	Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 133-141.	2.0	11
166	Burnout, Moral Distress, Work-Life Balance, and Career Satisfaction among Hematopoietic Cell Transplantation Professionals. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 849-860.	2.0	108
167	Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. <i>British Journal of Haematology</i> , 2018, 182, 916-920.	1.2	59
168	1563. Relationship of Cumulative Viral Burden of Adenovirus with Mortality in Allogeneic Hematopoietic Cell Transplant Recipients with Early Adenovirus Viremia. <i>Open Forum Infectious Diseases</i> , 2018, 5, S486-S487.	0.4	0
169	Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	258
170	Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. <i>Journal of Hematology and Oncology</i> , 2018, 11, 127.	6.9	17
171	Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2018, 2, 299-307.	2.5	69
172	Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2517-2522.	2.0	13
173	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (â€•CBF) Tj ETQq, 1 0.784314 rgBT 1.8 17	1.8	17
174	Loss of Microbiota Diversity after Autologous Stem Cell Transplant Is Comparable to Injury in Allogeneic Stem Cell Transplant. <i>Blood</i> , 2018, 132, 608-608.	0.6	9
175	The Prognostic Calculator Easix Predicts Acute Gvhd, Non-Relapse Mortality and Overall Survival in Adult Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT. <i>Blood</i> , 2018, 132, 2069-2069.	0.6	4
176	A Simple Geriatric Vulnerability Index for Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 2176-2176.	0.6	1
177	Burden and Impact of Geriatric Syndromes Associated with Allogeneic Hematopoietic Cell Transplantation in Older Adults. <i>Blood</i> , 2018, 132, 3370-3370.	0.6	0
178	The effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemia. <i>Haematologica</i> , 2017, 102, 941-947.	1.7	15
179	Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. <i>Blood</i> , 2017, 129, 1380-1388.	0.6	209
180	Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant. <i>Leukemia and Lymphoma</i> , 2017, 58, 1859-1871.	0.6	54

#	ARTICLE	IF	CITATIONS
181	Prospective Evaluation of Unrelated Donor Cord Blood and Haploidentical Donor Access Reveals Graft Availability Varies by Patient Ancestry: Practical Implications for Donor Selection. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 965-970.	2.0	31
182	Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1117-1121.	2.0	32
183	Phase I multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease. <i>Blood</i> , 2017, 129, 3256-3261.	0.6	34
184	Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Older Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1078-1086.	2.0	22
185	Ex Vivo CD34+â€œSelected T Cellâ€œDepleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 452-458.	2.0	35
186	Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2017, 29, 474-483.	1.1	12
187	T Cell Depletion as an Alternative Approach for Patients 55 Years or Older Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1685-1694.	2.0	12
188	The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34+â€œSelected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2004-2011.	2.0	11
189	Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1879-1886.	2.0	16
190	A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2088-2095.	2.0	9
191	Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies. <i>Journal of Medical Economics</i> , 2017, 20, 1244-1251.	1.0	15
192	Co-Infections by Double-Stranded DNA Viruses after Ex Vivo T Cellâ€œDepleted, CD34+ Selected Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1759-1766.	2.0	32
193	Real-World Economic Burden Associated with Transplantation-Related Complications. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1788-1794.	2.0	14
194	Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34 + Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 67-74.	2.0	24
195	Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 1650-1659.	0.8	252
196	Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cellâ€œReplete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2017, 35, 3002-3009.	0.8	255
197	Donor and recipient sex in allogeneic stem cell transplantation: what really matters. <i>Haematologica</i> , 2016, 101, 1260-1266.	1.7	54
198	Detection of human norovirus in intestinal biopsies from immunocompromised transplant patients. <i>Journal of General Virology</i> , 2016, 97, 2291-2300.	1.3	85

#	ARTICLE	IF	CITATIONS
199	The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≥12 months. British Journal of Haematology, 2016, 173, 260-264.	1.2	12
200	Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. British Journal of Haematology, 2016, 174, 235-248.	1.2	115
201	Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa. Biology of Blood and Marrow Transplantation, 2016, 22, 1449-1454.	2.0	8
202	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biology of Blood and Marrow Transplantation, 2016, 22, 1348-1356.	2.0	76
203	Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood, 2016, 127, 938-947.	0.6	246
204	Rapid identification of cytokine release syndrome after haploidentical PBSC transplantation and successful therapy with tocilizumab. Bone Marrow Transplantation, 2016, 51, 1620-1621.	1.3	17
205	Timing Is Everything: Combining Post-Transplantation Adoptive Cell Therapy and Tumor Vaccines. Biology of Blood and Marrow Transplantation, 2016, 22, 2113-2114.	2.0	0
206	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 2117-2125.	2.0	87
207	Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. Biology of Blood and Marrow Transplantation, 2016, 22, 1915-1925.	2.0	130
208	Cytomegalovirus Infection after CD34+-Selected Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1480-1486.	2.0	29
209	Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 705-709.	2.0	112
210	Social Media and the Adolescent and Young Adult (AYA) Patient with Cancer. Current Hematologic Malignancy Reports, 2016, 11, 449-455.	1.2	91
211	Reprint of: Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. Biology of Blood and Marrow Transplantation, 2016, 22, S9-S14.	2.0	0
212	Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case Forum. Biology of Blood and Marrow Transplantation, 2016, 22, 564-570.	2.0	8
213	Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. Biology of Blood and Marrow Transplantation, 2016, 22, 17-22.	2.0	16
214	Comparable Survival and Incidence of Toxicity for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 1236-1236.	0.6	0
215	Prognostic Factors of CLL Patients Undergoing Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation in the Immunochemotherapy Era. Blood, 2016, 128, 5865-5865.	0.6	0
216	In Vivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children. Biology of Blood and Marrow Transplantation, 2015, 21, 2173-2179.	2.0	21

#	ARTICLE	IF	CITATIONS
217	Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin. <i>Clinical Infectious Diseases</i> , 2015, 61, S652-S661.	2.9	32
218	Immune reconstitution following stem cell transplantation. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 215-219.	0.9	71
219	High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. <i>Blood</i> , 2015, 125, 199-205.	0.6	109
220	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. <i>Blood</i> , 2015, 126, 1033-1040.	0.6	565
221	Social Media and the Practicing Hematologist: Twitter 101 for the Busy Healthcare Provider. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 405-412.	1.2	46
222	Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients. <i>Journal of Clinical Medicine</i> , 2015, 4, 488-503.	1.0	16
223	CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2106-2114.	2.0	49
224	Bone Marrow or Peripheral Blood for Reduced-Intensity Conditioning Unrelated Donor Transplantation. <i>Journal of Clinical Oncology</i> , 2015, 33, 364-369.	0.8	51
225	Intestinal <i>Blautia</i> Is Associated with Reduced Death from Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1373-1383.	2.0	619
226	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1746-1753.	2.0	48
227	Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 920-925.	2.0	33
228	Immune reconstitution after cord blood transplantation: peculiarities, clinical implications and management strategies. <i>Cytotherapy</i> , 2015, 17, 711-722.	0.3	36
229	Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 971-983.	2.0	65
230	Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era. <i>Bone Marrow Transplantation</i> , 2015, 50, 1293-1298.	1.3	15
231	Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2160-2166.	2.0	31
232	High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1985-1993.	2.0	40
233	Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma. <i>Blood Reviews</i> , 2015, 29, 143-152.	2.8	8
234	Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 663-670.	0.6	18

#	ARTICLE	IF	CITATIONS
235	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) after Treatment with Programmed Cell Death 1 (PD-1) Inhibitors. <i>Blood</i> , 2015, 126, 2018-2018.	0.6	5
236	Successful Treatment of Peripheral T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: A Large Single-Center Experience. <i>Blood</i> , 2015, 126, 4392-4392.	0.6	4
237	A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies. <i>Leukemia and Lymphoma</i> , 2014, 55, 2739-2747.	0.6	9
238	Stem Cell Transplantation in Hodgkin Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 1097-1112.	0.9	8
239	A Phase II Study of a Nonmyeloablative Allogeneic Stem Cell Transplant with Peritransplant Rituximab in Patients with B-Cell Lymphoid Malignancies: Favorably Durable Event-Free Survival in Chemosensitive Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 354-360.	2.0	35
240	Frequent Human Herpesvirus-6 Viremia But Low Incidence of Encephalitis in Double-Unit Cord Blood Recipients Transplanted Without Antithymocyte Globulin. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 787-793.	2.0	43
241	Favorable Outcomes in Elderly Patients Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2004-2009.	2.0	52
242	Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1262-1273.	2.0	176
243	Double-Unit Cord Blood (CB) Transplantation Combined with Haplo-Identical CD34+ Cells Results in 100% CB Engraftment with Enhanced Myeloid Recovery. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S138-S139.	2.0	3
244	Conditioning Chemotherapy Dose Adjustment in Obese Patients: A Review and Position Statement by the American Society for Blood and Marrow Transplantation Practice Guideline Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 600-616.	2.0	68
245	Challenges and Potential Solutions for Recruitment and Retention of Hematopoietic Cell Transplantation Physicians: The National Marrow Donor Program's System Capacity Initiative Physician Workforce Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 617-621.	2.0	16
246	Low CD34 Dose Is Associated with Poor Survival after Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1418-1425.	2.0	40
247	The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2014, 124, 1174-1182.	0.6	711
248	Analysis of 129 Myeloablative Double-Unit Cord Blood Transplantation Recipients Demonstrates an Independent Association Between Non-Dominant Unit TNC Dose and Engraftment Suggesting a Facilitation Effect. <i>Blood</i> , 2014, 124, 2459-2459.	0.6	1
249	A Novel Reduced-Intensity Conditioning Regimen Induces a High Incidence of Sustained Donor-Derived Neutrophil and Platelet Engraftment after Double-Unit Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 799-803.	2.0	63
250	Strategies to improve post-transplant immunity. , 2013, , 123-142.		1
251	T Cell-Depleted Stem Cell Transplantation for Adults with High-Risk Acute Lymphoblastic Leukemia: Long-Term Survival for Patients in First Complete Remission with a Decreased Risk of Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 208-213.	2.0	41
252	Clinical applications of palifermin: amelioration of oral mucositis and other potential indications. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 1371-1384.	1.6	51

#	ARTICLE	IF	CITATIONS
253	Enhanced Responses to Tumor Immunization Following Total Body Irradiation Are Time-Dependent. PLoS ONE, 2013, 8, e82496.	1.1	11
254	T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HCT) For Adult Patients With Acute Myelogenous Leukemia (AML) In First and Second Remission: Long-Term Disease Free Survival(DFS) With a Significantly Reduced Risk Of Graft-Versus-Host Disease(GvHD). Blood, 2013, 122, 3387-3387.	0.6	0
255	Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant. Leukemia and Lymphoma, 2012, 53, 1124-1129.	0.6	41
256	Editorial Commentary: Adenovirus Viremia and Infection After Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplant: Should We Institute a Routine Screening Program?. Clinical Infectious Diseases, 2012, 55, 1371-1372.	2.9	6
257	Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood, 2012, 120, 4882-4891.	0.6	165
258	Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure. Biology of Blood and Marrow Transplantation, 2012, 18, 1255-1264.	2.0	27
259	Intestinal Domination and the Risk of Bacteremia in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Infectious Diseases, 2012, 55, 905-914.	2.9	779
260	Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation: Is It Time to Revisit How Patients Are Monitored?. Biology of Blood and Marrow Transplantation, 2012, 18, 1617-1619.	2.0	5
261	T Cell-Depleted Unrelated Donor Stem Cell Transplantation Provides Favorable Disease-Free Survival for Adults with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2011, 17, 1335-1342.	2.0	74
262	Reduced Late Mortality Risk Contributes to Similar Survival after Double-Unit Cord Blood Transplantation Compared with Related and Unrelated Donor Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1316-1326.	2.0	72
263	Serious Infection Risk and Immune Recovery after Double-Unit Cord Blood Transplantation Without Antithymocyte Globulin. Biology of Blood and Marrow Transplantation, 2011, 17, 1460-1471.	2.0	100
264	Improved Survival in Patients with Refractory Cytopenias (Low Risk Myelodysplastic Syndrome - MDS) Treated with Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants (allo TCD-HSCTs). Blood, 2011, 118, 3831-3831.	0.6	0
265	Cytokine-FC Fusion Genes as Molecular Adjuvants for DNA Vaccines. Methods in Molecular Biology, 2010, 651, 131-155.	0.4	4
266	Disease-Free Survival After Cord Blood (CB) Transplantation Is Not Different to That After Related or Unrelated Donor Transplantation in Patients with Hematologic Malignancies.. Blood, 2009, 114, 2296-2296.	0.6	6
267	Transplantation in Remission Improves the Disease-Free Survival of Patients with Advanced Myelodysplastic Syndromes Treated with Myeloablative T Cell-Depleted Stem Cell Transplants from HLA-Identical Siblings. Biology of Blood and Marrow Transplantation, 2008, 14, 458-468.	2.0	64
268	Phase I/II Study of GM-CSF DNA as an Adjuvant for a Multi-peptide Cancer Vaccine in Patients With Advanced Melanoma. Molecular Therapy, 2008, 16, 2022-2029.	3.7	84
269	T cell-depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood, 2007, 110, 4552-4559.	0.6	106
270	Clinical strategies to enhance T cell reconstitution. Seminars in Immunology, 2007, 19, 289-296.	2.7	64



#	ARTICLE	IF	CITATIONS
271	Intravenous Busulfan and Melphalan, Tacrolimus, and Short-Course Methotrexate Followed by Unmodified HLA-Matched Related or Unrelated Hematopoietic Stem Cell Transplantation for the Treatment of Advanced Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 235-244.	2.0	25
272	Analysis of 121 Allograft Recipients for the Treatment of Lymphoma: Progressive Disease by Functional and/or CT Imaging Is a Critical Determinant of Survival.. <i>Blood</i> , 2007, 110, 1658-1658.	0.6	0
273	Immunomodulatory Molecules of the Immune System. , 2007, , 67-121.		0
274	Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. <i>Nature Medicine</i> , 2006, 12, 1039-1047.	15.2	173
275	Adjuvanticity of Plasmid DNA Encoding Cytokines Fused to Immunoglobulin Fc Domains. <i>Clinical Cancer Research</i> , 2006, 12, 5511-5519.	3.2	45
276	DNA Immunization against Tissue-Restricted Antigens Enhances Tumor Immunity after Allogeneic Hemopoietic Stem Cell Transplantation. <i>Journal of Immunology</i> , 2006, 177, 4159-4167.	0.4	15
277	Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005, 22, 749-760.	0.5	6
278	Results of T Cell Depleted (TCD) Myeloablative Hematopoietic Stem Cell Transplants (HSCT) in Patients with Hematologic Malignancies ≥ 55 yrs of Age.. <i>Blood</i> , 2005, 106, 3660-3660.	0.6	0
279	DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mouse Models of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).. <i>Blood</i> , 2004, 104, 304-304.	0.6	0
280	CD4 Help and Tumor Immunity: Beyond the Activation of Cytotoxic T Lymphocytes. <i>Annals of Surgical Oncology</i> , 2004, 11, 881-882.	0.7	6
281	Granulocyte-Macrophage Colony Stimulating Factor: An Adjuvant for Cancer Vaccines. <i>Hematology</i> , 2004, 9, 207-215.	0.7	65
282	DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mice Following Sub-Lethal Irradiation and Immune Reconstitution.. <i>Blood</i> , 2004, 104, 3057-3057.	0.6	0
283	GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines. <i>Cytokines, Cellular &amp; Molecular Therapy</i> , 2002, 7, 125-133.	0.3	29
284	Melanoma Vaccines. <i>Cancer Investigation</i> , 2002, 20, 1012-1026.	0.6	13
285	Redundant and Alternative Roles for Activating Fc Receptors and Complement in an Antibody-Dependent Model of Autoimmune Vitiligo. <i>Immunity</i> , 2002, 16, 861-868.	6.6	64
286	Strategies to overcome immune ignorance and tolerance. <i>Seminars in Cancer Biology</i> , 2002, 12, 63-71.	4.3	46
287	Serum enhances the ex vivo generation of HIV-specific cytotoxic T cells. , 2000, 50, 521-528.		7
288	Serum enhances the ex vivo generation of HIV-specific cytotoxic T cells. <i>Biotechnology and Bioengineering</i> , 1996, 50, 521-528.	1.7	7

#	ARTICLE	IF	CITATIONS
289	A Vaccinia-gp160-Based Vaccine But Not a gp160 Protein Vaccine Elicits Anti-gp160 Cytotoxic T Lymphocytes in Some HIV-1 Seronegative Vaccinees. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1995, 10, 277-285.	0.3	23